Candel Therapeutics, Inc.
CADL
$4.76
$0.224.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 24.67M | 31.62M | 31.24M | 32.21M | 33.80M |
| Gross Profit | -24.67M | -31.62M | -31.24M | -32.21M | -33.80M |
| SG&A Expenses | 14.40M | 14.32M | 13.99M | 14.04M | 14.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.63M | 35.16M | 35.26M | 36.27M | 38.00M |
| Operating Income | -32.63M | -35.16M | -35.26M | -36.27M | -38.00M |
| Income Before Tax | -55.18M | -52.20M | -49.99M | -37.37M | -37.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.18 | -52.20 | -49.99 | -37.37 | -37.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.18M | -52.20M | -49.99M | -37.37M | -37.94M |
| EBIT | -32.63M | -35.16M | -35.26M | -36.27M | -38.00M |
| EBITDA | -31.64M | -34.16M | -34.27M | -35.29M | -37.04M |
| EPS Basic | -1.75 | -1.74 | -1.70 | -1.29 | -1.31 |
| Normalized Basic EPS | -1.08 | -1.08 | -1.05 | -0.80 | -0.81 |
| EPS Diluted | -1.75 | -1.74 | -1.70 | -1.29 | -1.31 |
| Normalized Diluted EPS | -1.08 | -1.08 | -1.05 | -0.80 | -0.81 |
| Average Basic Shares Outstanding | 126.65M | 120.07M | 116.98M | 116.02M | 115.74M |
| Average Diluted Shares Outstanding | 126.65M | 120.07M | 116.98M | 116.02M | 115.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |